SpencerKSullivanMD

Pediatric Anemia and Red Blood Cell Hematology, Pediatric Coagulation Disorder Hematology, Pediatric Platelet Disorder Hematology

CEO, Mississippi Center for Advanced Medicine

Dr. Sullivan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
7730 Old Canton Rd
Bldg B
Madison, MS 39110
Phone+1 601-499-0935

Fax+1 601-499-0936

Children's Hospital of PhiladelphiaFellowship, Pediatric Hematology/Oncology, 2009 - 2012
University of Virginia Medical CenterFellowship, Blood Banking/Transfusion Medicine, 2008 - 2009
University of Virginia Medical CenterResidency, Pediatrics, 2005 - 2008
University of North Carolina at Chapel Hill School of MedicineClass of 2005

PubMed

90 citations
Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A.
Lindsey A. George, Paul E Monahan, M Elaine Eyster, Spencer K. Sullivan, Margaret V Ragni
The New England Journal of Medicine. 2021-11-18
10 citations
Infused factor VIII-expressing platelets or megakaryocytes as a novel therapeutic strategy for hemophilia A.
Randolph B. Lyde, Hyun Sook Ahn, Karen K. Vo, Danuta Jarocha, John Tkaczynski
Blood Advances. 2019-05-14
454 citations
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant.
Lindsey A. George, Spencer K. Sullivan, Adam Giermasz, John E.J. Rasko, Benjamin J. Samelson-Jones
The New England Journal of Medicine. 2017-12-06

Abstracts/Posters

Efficacy and Safety in 15 Hemophilia B Patients Treated with the AAV Gene Therapy Vector Fidanacogene Elaparvovec and Followed for at Least 1 Year
Spencer K. Sullivan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Gene Therapy SPK-8016 Shows Early Promise for Severe Hemophilia AFebruary 8th, 2021
Spark Therapeutics Announces Updated Data from First Cohort in Hemophilia B Phase 1/2 Trial Demonstrating Consistent, Sustained Therapeutic Levels of Factor IX ActivityJune 13th, 2016

MCAM Websitehttp://www.msadvancedmedicine.com
MCAM Facebookhttps://www.facebook.com/MississippiAdvancedMedicine/?ref=bookmarks